Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Phentolamine Mesylate
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Recipient : Ocuphire Pharma
Deal Size : $21.1 million
Deal Type : Merger
Rexahn and Ocuphire Enter into Definitive Merger Agreement
Details : This merger supports Ocuphire for advancement of its late-clinical stage small molecule ophthalmic pipeline including its Nyxol® Eye Drops, a once-daily eye drop formulation of phentolamine mesylate designed to reduce pupil diameter and improve visual a...
Brand Name : Nyxol
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 18, 2020
Lead Product(s) : Phentolamine Mesylate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Recipient : Ocuphire Pharma
Deal Size : $21.1 million
Deal Type : Merger
Lead Product(s) : RX-5902
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : Merck & Co
Deal Size : Undisclosed
Deal Type : Termination
Rexahn Pharmaceuticals Terminates Breast Cancer Study with Merck
Details : The company had previously disclosed that it was evaluating the development strategy for RX-5902, including whether to proceed with the trial.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 09, 2020
Lead Product(s) : RX-5902
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : Merck & Co
Deal Size : Undisclosed
Deal Type : Termination
LOOKING FOR A SUPPLIER?
Reset All
